Simile has raised $400M across 2 funding rounds, plus 1 undated round. The latest round valued Simile at $2B post-money, with Greenoaks on the lead line.
Simile raised a $100 million Series A led by Index Ventures shortly after emerging from stealth, then closed a $200 million Series B just five months later at a $2 billion valuation.
2 funding rounds, the latest highlighted.
Simile was founded in 2026, United States.
No date is disclosed for this round.
A primary round — the company sells new shares to investors it selects. $100M raised, led by Index Ventures.
Index Ventures, Hanabi, Bain Capital Ventures, A*, Factory, Definition, CVS Health Ventures. $200M raised, led by Greenoaks.
No filing has been made.
2 dated rounds, newest first.
Index VenturesLEAD
GreenoaksLEADHHanabi
Bain Capital VenturesAA*FFactoryDDefinition
CVS Health VenturesThe closest ai synthetic-user simulation for market/product research peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Simile is a private company; its shares do not trade on a public exchange.
The last valuation is $2B.
Lead investors for each round are in the funding timeline.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
